科德數控(688305.SH):2023年公司規劃整機產能達產350台
格隆匯9月19日丨科德數控(688305.SH)接受現場調研時表示,從產能規模來看,2022年公司實現高端五軸聯動數控機牀產量230台,產品類型覆蓋五軸立式加工中心、五軸卧式加工中心、五軸銑車複合加工中心等。同時銀川工廠實現電主軸近400台套的產能建設,既滿足了公司整機裝配的需求,又實現了對外的單獨銷售及售後服務。2023年公司規劃整機產能達產350台。上半年,公司整機產量同比增長27.08%;下半年,公司也會積極響應下游客户的需求,合理利用產能資源,加快產能建設,以滿足各行業日益提升的對五軸聯動數控機牀的緊迫需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.